What TG Therapeutics, Inc. Shareholders Need to Know About the Lead Plaintiff Process Under the PSLRA

Contact TG Therapeutics stock loss lawyer Timothy L. Miles today about an TG Therapeutics class action lawsuit 

The TG Therapeutics class action lawsuit was file by an investor who suffered losses TG Therapeutics stock and is captioned Shapiro v. TG Therapeutics, Inc., No. 22-cv-06106 (S.D.N.Y.).  The TG Therapeutics class action lawsuit charges TG Therapeutics and certain of its top executive officers with violations of the Securities Exchange Act of 1934.

The TG Therapeutics class action lawsuit seeks to represent purchasers or acquirers of TG Therapeutics, Inc. (NASDAQ: TGTX) securities between January 15, 2020 and May 31, 2022, inclusive (the “Class Period”).

If you suffered losses in TG Therapeutics stock and wish to serve as lead plaintiff of the TG Therapeutics class action lawsuit, or have any other questions, please provide your information by completing the contact form at the bottom of the page.  You can also contact TG Therapeutics Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at [email protected]. 
​
Lead plaintiff motions for the TG Therapeutics class action lawsuit must be filed with the court no later than September 16, 2022. Read on for more on the lead plaintiff process.

The Lead Plaintiff Process in the TG Therapeutics Class Action Lawsuit

The Private Securities Litigation Reform Act of 1995 (“PSLRA) permits any investor who purchased and suffered losses in TG Therapeutics stock to seek appointment as lead plaintiff in the TG Therapeutics class action lawsuit. Under the PSLRA, after a complaint is filed, a plaintiff has no later than 20 days to circulate notice to shareholders about the filing of the complaint notifying shareholders that “not later than 60 days after the date on which the notice is published, any member of the purported class may move the court to serve as lead plaintiff of the purported class.” 15 U.S. Code § 78u–4(a)(3)(A)(i)-(iii.).  Thus, pursuant to the PSLRA, Lead plaintiff motions for the TG Therapeutics class action lawsuit must be filed with the court no later than October 4, 2022 after publication of the notice.
​
A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  15 U.S. Code § 78u–4(a)(3)(B)(iii)(I)(bb)-(cc). A lead plaintiff is a fiduciary and acts on behalf of all other class members in directing the class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the class action lawsuit.  An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in TG Therapeutics stock, and have further questions, contact TG Therapeutics Stock Loss Lawyer Timothy L. Miles today.​

Lead plaintiff motions for the TG Therapeutics class action
lawsuit must be filed with the court no later than September 16, 2022

Contact an TG Therapeutics Stock Loss Lawyer if You Suffered Losses in TG Therapeutics Stock

If you suffered losses in TG Therapeutics stock, contact TG Therapeutics stock loss lawyer Timothy L. Miles today about an TG Therapeutics class action lawsuit and see what a TG Therapeutics stock loss lawyer can do for you.

Timothy L. Miles, Esq.

Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles was recentely selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, and more.